



BERYL DRUGS LIMITED
Gr. Floor, 133, Kanchan Bagh, Indore (M.P.) – 452 001.
Tel./ Fax 0731-3961510
E-mail : beryldrugs25@yahoo.com

ANNEXURE I

Part I Submission of Unaudited/ Audited Financial Result by Companies Other than Banks

Statement of standalone / Consolidated / Audited Result for the Quarter/ year ended 30/06/2017


(Rs in 000)

Particulars	3 months ended	Preceding 3	Corresponding 3	Year to date	Year to date	Previous year
	(30-06-2017)	months ended	months ended in	figures for current	figures for	ended
		(31-03-2017)	the previous year	period ended	previous period	(31-03-2017)
		(30-06-2016)	(30-06-2016)	(30-06-2017)	ended	(30-06-2016)
(Refer Notes Below)	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 Revenue From Operations						
Net sales or Revenue from Operations	48470.000	23783.000	30400.000	48470.000	30400.000	109936.000
Other operating revenues	378.000	1341.000	561.000	378.000	561.000	2607.000
Total Revenue from operations (net)	48848.000	25124.000	30961.000	48848.000	30961.000	112543.000
2 Expenses						
(a) Cost of materials consumed	26012.000	-2583.000	23292.000	26012.000	23292.000	69426.000
(b) Purchases of stock-in-trade	0.000	0.000	0.000	0.000	0.000	0.000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	10905.000	1467.000	504.000	10905.000	504.000	-4459.000
(d) Employee benefit expense	1655.000	1819.000	2596.000	1655.000	2596.000	9787.000
(e) Finance costs	373.000	469.000	536.000	373.000	536.000	2009.000
(f) Depreciation and amortisation expense	1000.000	770.000	1000.000	1000.000	1000.000	3776.000
(g) Other Expenses	7616.000	23177.000	1610.000	7616.000	1610.000	30303.000
Total expenses	47561.000	25119.000	29538.000	47561.000	29538.000	110842.000
3 Profit (loss) from operations before exceptional and extraordinary items and tax	1287.000	5.000	1423.000	1287.000	1423.000	1701.000
4 Exceptional items	0.000	0.000	0.000	0.000	0.000	0.000
5 profit (loss) before extraordinary items and tax	1287.000	5.000	1423.000	1287.000	1423.000	1701.000
6 Extraordinary items	0.000	0.000	0.000	0.000	0.000	0.000
7 Profit (loss) before tax	1287.000	5.000	1423.000	1287.000	1423.000	1701.000
8 Tax Expense						
Current tax	320.000	207.000	200.000	320.000	200.000	874.000
Deferred tax	0.000	0.000	0.000	0.000	0.000	-339.000
Total Tax Expenses	320.000	207.000	200.000	320.000	200.000	535.000
9 Net Profit (loss) for the period from continuing operations	967.000	-202.000	1223.000	967.000	1223.000	1166.000
10 Net Profit (loss) from discontinuing operations before tax	0.000	0.000	0.000	0.000	0.000	0.000
11 Tax Expense of discontinuing operations	0.000	0.000	0.000	0.000	0.000	0.000
12 Net Profit (loss) from discontinuing operations after tax	0.000	0.000	0.000	0.000	0.000	0.000
13 Net Profit (loss) for the Period	967.000	-202.000	1223.000	967.000	1223.000	1166.000
14 Details of equity share capital						
Paid-up equity share capital	50717.000	50717.000	50717.000	50717.000	50717.000	50717.000
Face value of equity share capital	10.000	10.000	10.000	10.000	10.000	10.000
15 Earnings per share						
i Basic earnings per share before extraordinary items	0.191	0.000	0.241	0.191	0.241	0.230
ii Diluted earnings per share before extraordinary items	0.191	0.000	0.241	0.191	0.241	0.230

Notes :

- The Standalone results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meeting held on 07th July 2017.
- In accordance with the requirements of Clause 41 of the Listing Agreement with the Stock Exchange, the Statutory Auditors have performed a limited review of the Company's financial results for the quarter ended June 30, 2017 there are no qualifications.
- The Income from Operations is from one segment namely "Pharmaceutical Industry".
- Previous period exp. have been regrouped / rearranged, wherever necessary.
- Taxes and depreciation are calculated on proportionate basis on annual estimated basis.
- There were no Investors complaints pending at the beginning of the quarter and one complaint were received during the quarter ended June 06, 2017.

Place : Indore
Date : 07.07.2017



SUBHASH CHAND JAIN ANURAG & ASSOCIATES
CHARTERED ACCOUNTANTS

4, Archana Apartment,
8-B, Ratlam Kothi, Indore - 452 001 (M.P.)
Ph: 2519439, 2527682
Mob No: 93021-23882
Email: scjainca2004@yahoo.com



LIMITED REVIEW REPORT

To
The Board of Directors
Beryl Drugs Limited
133, Kanchan Bagh, Indore (M.P.)

We have reviewed the accompanying statement of unaudited financial results of **BERYL DRUGS LIMITED** for the period ended **30/06/2017**. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI(Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR- SUBHASH CHAND JAIN ANURAG & ASSOCIATES
CHARTERED ACCOUNTANTS
FRN-004733C



Date: 06/07/2017
Place: Indore


(BADAL BANGUR)
PARTNER
M. No. 423724